Shinpoong Pharmaceutical Co.,Ltd (019175.KS)
- Previous Close
23,650.00 - Open
23,700.00 - Bid --
- Ask --
- Day's Range
23,700.00 - 24,050.00 - 52 Week Range
16,150.00 - 39,400.00 - Volume
3,240 - Avg. Volume
48,873 - Market Cap (intraday)
672.056B - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2020
- 1y Target Est
--
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
shinpoong.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 019175.KS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 019175.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 019175.KS
Valuation Measures
Market Cap
1.23T
Enterprise Value
1.21T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.11
Price/Book (mrq)
4.56
Enterprise Value/Revenue
6.05
Enterprise Value/EBITDA
-30.44
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.63%
Return on Assets (ttm)
-8.33%
Return on Equity (ttm)
-19.04%
Revenue (ttm)
200.23B
Net Income Avi to Common (ttm)
-57.33B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
60.58B
Total Debt/Equity (mrq)
17.04%
Levered Free Cash Flow (ttm)
-26.77B
Company Insights: 019175.KS
019175.KS does not have Company Insights